Navigation Links
pH 200 series, F 260 Handheld, pH/Temp/mV Meter

ProductspH 200 series, F 260 Handheld, pH/Temp/mV Meter
Company Beckman Coulter, Inc.
Item pH 200 series, F 260 Handheld, pH/Temp/mV Meter
Features Inquire
Description F 260 is a highly accurate portable system for pH, mV (ORP), relative mV and temperature measurements. Temperature compensated pH results can be obtained when used with a temperature probe (ATC) or a 3-in-1 electrode. • This GLP/GMP compliant system includes an RS-232 interface to connect to a printer or a computer. Up to 100 data sets can be stored for later recall, printing or transfer to a computer. • Fast and easy one- to five-point calibration with Auto-Find automatic buffer recognition for five buffers (pH 1.68, 4.00, 7.00, 10.01 and 12.45) and Auto-Read for locking onto stable readings. Standard buffers can be substituted with alternate buffers (pH 6.86, 7.41, 9.18 and 11.88) while maintaining automatic buffer recognition and temperature compensation. • Continuous display of calibration buffers. The temperature can be displayed in either °C or °F. The system provides audible support that can be turned on or off by the user. 100 data storage locations are available and the user is able to determine an individual storage location, if selected. • GLP/GMP features such as date and time stamp for each calibration and measurement, link of each result to the appropriate calibration data and printout of calibration header for each group of samples are included. A visual and audible re-calibration alert after a user-specified time assures accurate results at all times. • The LCD displays results, temperature, status messages and icons.
Info Beckman Coulter, Inc.
Customer Service: (800) 742-2345
Web site: http://www.beckmancoulter.com

Related medicine products :

1. pH 200 series, F 295 Handheld, Water-Proof pH/Temp/mV/ISE Meter
2. pH 200 series, F 265 Handheld, Water-Proof pH/Temp/mV Meter With Electrode
3. pH 200 series, F 255 Handheld, Water-Proof pH/Temp/mV Meter
4. pH 200 series, F 250 Handheld, pH/Temp/mV Meter
5. pH 200 series, F 265 Handheld, Water-Proof pH/Temp/mV Meter
6. pH 200 series, F 240 Handheld, pH/Temp Meter
7. 1-Meter Roll-Up Tangent Screen
8. HemoSite Meter
9. Retinal Acuity Meter, RAM®
10. Retinal Acuity Meter, RAM
11. HemoSite® Meter
Volume range 1-5 ml. Designed for use with large laboratory vessels.
300 L, Bulk Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
...easy way to order tips. Each box contains 1000 tip...ains 200 tips (4 bags of 50 tips). Also available ...s per pack. Bulk Packs are sealed with a tamper-pr...ess to Gilsons Diamond Tips. Bulk Packs are closed...
Medicine Products:
(Date:11/21/2008)...ov. 21 New research at ...smokeless, spitless tobacco product aimed at young...ound that RJ Reynolds, Camel Snus - touted as a so...ins surprisingly high levels of nicotine. , ,...her snuff products," said Bruce Adkins of the stat...
(Date:11/21/2008)..., Nov. 21 Today, prescri...vention in treating 88 percent of patients sufferi...s treated for a chronic condition account for 96 p...rcent of all medical costs. A proprietary new pha...alth Solutions, Inc. (NYSE: MHS ) significantly ...
(Date:11/21/2008)...ewswire/ -- In a statewide survey, 33 physicians c... Surgery at Presbyterian Hospital of Dallas were h...ng of " Super Doctors ." , , Each year, the...ssional Media, Inc. to survey more than 38,000 med...k, "If you needed medical care, which doctor would...
(Date:11/21/2008)...cco use is more prevalent and smoking cessation le...eractivity Disorder (A.D.H.D.) In a study of smok...oms, those who exhibited elevated hyperactivity an... lower quit rates after 8 weeks than those with in...H.D. symptoms. The study, now available online in...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
... two research papers have shown that use of the dr...gens for vaginal atrophy reduces the incidence of ...se model and researchers are planning for a clinic...es at UC Davis compared the ability of ospemifene,...
...ice will have to reduce their weight and stress by...that most of the police personnel’s in a district ...ss at work. // Highly feared bandit gang operate ... districts of Shivpuri which forms part of the Cha...
... imaging can now be used to predict the risk for a...lar arrhythmia. Patients whose muscle wall thickne...ne // times more likely to likely to test positiv...ins Institute. If the findings can be extrapolate...
...ers to the enhancement in action or effect of a pa...he drugs combined. The phenomenon could be exploit...u is posing a serious threat across different regi...scribed drug for seasonal flu, because it will be ...
Other Medicine News:Health News:Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention 2Health News:MRI can predict risk of cardiac arrhythmia by identification of scar tissue, 2Health News:Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid 2
(Date:11/19/2008)...ieve statistical significance , , ISELIN, N...rporation (Nasdaq: PARS ) today announced result...NanoEmulsion (NE) drug delivery technology formula...The multi-center, randomized, double-blinded, plac...cacy of the Company,s 3% Diclofenac Diethanolamine...
(Date:11/19/2008)...wire/ -- Isogen, a contract development and,manuf...nnounced the first,phase launch of its contract f...ically address the process, facility and capacity ...highly-niched, low-volume clinical and,early-stag... Companies can invest over $100 million and fou...
(Date:11/18/2008)... to learn more, make a donation or send a Christm...Newswire-USNewswire/ -- Millions will receive Chri...e American Lung Association. These decorative holi...tion dating back to 1907 when the Lung Association... "Most Americans alive today have no vivid memorie...
(Date:11/18/2008)...008 Faces of Influenza survey underscores that mot...nza; Mother and Gold Medalist Kristi Yamaguchi joi...ewswire/ -- While 78 percent of mothers in the Uni...ally life-threatening disease that can strike anyo... get vaccinated this season, according to a new su...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6West Nile virus spread through nerve cells linked to serious complication 881 1West Nile virus spread through nerve cells linked to serious complication 881 2West Nile virus spread through nerve cells linked to serious complication 881 3Reflux Can Precipitate Chest Pain Cough 4063 1Reflux Can Precipitate Chest Pain Cough 4063 2Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital Acquired Infections 4060 1Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital Acquired Infections 4060 2Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital Acquired Infections 4060 3Body Image Has Little Influence on Desire for Plastic Surgery ASPS Study Reveals 4057 1Body Image Has Little Influence on Desire for Plastic Surgery ASPS Study Reveals 4057 2Body Image Has Little Influence on Desire for Plastic Surgery ASPS Study Reveals 4057 3
...luable Patients Show Stabilized Disease; Biomarker...otential for,Patient Stratification --, GERMANTOWN...lon,Pharmaceuticals, Inc. , today announced contin...y of AVN944, for the treatment of,hematologic mali...im data indicate AVN944 is well tolerated, has dos...
...-(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporat...ative oncology and,cardiovascular surgical and dia...nary results from a multicenter Phase 2 clinical,s... (Technetium,Tc99m DTPA-mannosyl-dextran). Lymphos...eing developed for use with handheld,gamma detecti...
Other Medicine Technology:Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial 2Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial 3Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial 4Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial 5Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial 6Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint 2Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint 3